Gilead Sciences (GILD) Given a $94.00 Price Target by Maxim Group Analysts

Gilead Sciences (NASDAQ:GILD) has been given a $94.00 price target by analysts at Maxim Group in a report issued on Monday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target indicates a potential upside of 23.54% from the company’s previous close.

A number of other analysts also recently commented on GILD. Mizuho reissued a “buy” rating on shares of Gilead Sciences in a report on Friday, September 29th. Berenberg Bank reissued a “buy” rating and set a $86.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a report on Sunday, August 20th. Credit Suisse Group reissued a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a report on Thursday, December 7th. Cowen reissued an “outperform” rating and set a $90.00 price objective on shares of Gilead Sciences in a report on Thursday, August 31st. Finally, Leerink Swann reaffirmed a “market perform” rating and issued a $87.00 price target (up previously from $82.00) on shares of Gilead Sciences in a report on Wednesday, September 20th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $85.11.

Shares of Gilead Sciences (GILD) opened at $76.09 on Monday. The company has a market cap of $99,119.69, a PE ratio of 7.92, a P/E/G ratio of -1.27 and a beta of 1.13. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm’s revenue was down 13.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.75 earnings per share. analysts forecast that Gilead Sciences will post 8.53 EPS for the current year.

In other news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $82.56, for a total value of $6,054,372.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. In the last three months, insiders sold 494,999 shares of company stock valued at $37,404,139. Company insiders own 1.30% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Welch Investments LLC acquired a new position in Gilead Sciences during the third quarter worth approximately $108,000. Wealthcare Advisory Partners LLC acquired a new position in Gilead Sciences during the third quarter worth approximately $133,000. Penserra Capital Management LLC increased its position in Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the last quarter. Horan Capital Advisors LLC. acquired a new position in Gilead Sciences during the third quarter worth approximately $144,000. Finally, Hanson & Doremus Investment Management increased its position in Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares during the last quarter. 76.23% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Gilead Sciences (GILD) Given a $94.00 Price Target by Maxim Group Analysts” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.com-unik.info/2017/12/13/gilead-sciences-gild-given-a-94-00-price-target-by-maxim-group-analysts.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit